BeOne Medicines (ONC) Liabilities and Shareholders Equity (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $8.6 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 46.43% year-over-year to $8.6 billion in Q1 2026; TTM through Mar 2026 was $30.7 billion, a 31.61% increase from a year earlier, with the FY2025 full-year figure at $8.2 billion, up 38.3% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $8.6 billion, up from $8.2 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ONC reached as high as $8.6 billion in Q1 2026 and fell as low as $5.5 billion in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $6.5 billion across 5 years, with a median of $5.9 billion in 2024.
• Across the five-year window, Liabilities and Shareholders Equity plunged 35.78% in 2022 and surged 46.43% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $5.5 billion in 2022, then gained by 5.91% to $5.8 billion in 2023, then advanced by 1.99% to $5.9 billion in 2024, then surged by 38.3% to $8.2 billion in 2025, then advanced by 4.46% to $8.6 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $8.6 billion in Q1 2026, $8.2 billion in Q4 2025, and $7.6 billion in Q3 2025.